Dihydropyrimidine dehydrogenase deficiency secondary to polymorphisms in the DPYD gene can lead to significant toxicity associated with the administration of fluoropyrimidine chemotherapy. Here, DPYD is linked to dihydropyrimidine dehydrogenase deficiency.